Exact Mass: 336.9787
Exact Mass Matches: 336.9787
Found 62 metabolites which its exact mass value is equals to given mass value 336.9787,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
tenoxicam
M - Musculo-skeletal system > M01 - Antiinflammatory and antirheumatic products > M01A - Antiinflammatory and antirheumatic products, non-steroids > M01AC - Oxicams D018501 - Antirheumatic Agents > D000894 - Anti-Inflammatory Agents, Non-Steroidal > D016861 - Cyclooxygenase Inhibitors C78272 - Agent Affecting Nervous System > C241 - Analgesic Agent > C2198 - Nonnarcotic Analgesic D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents D002491 - Central Nervous System Agents > D000700 - Analgesics D000893 - Anti-Inflammatory Agents D004791 - Enzyme Inhibitors
Tenoxicam
Tenoxicam is only found in individuals that have used or taken this drug. It is an antiinflammatory agent with analgesic and antipyretic properties, and is used to treat osteoarthritis and control acute pain.The antiinflammatory effects of tenoxicam may result from the inhibition of the enzyme cycooxygenase and the subsequent peripheral inhibition of prostaglandin synthesis. As prostaglandins sensitize pain receptors, their inhibition accounts for the peripheral analgesic effects of tenoxicam. Antipyresis may occur by central action on the hypothalamus, resulting in peripheral dilation, increased cutaneous blood flow, and subsequent heat loss. M - Musculo-skeletal system > M01 - Antiinflammatory and antirheumatic products > M01A - Antiinflammatory and antirheumatic products, non-steroids > M01AC - Oxicams D018501 - Antirheumatic Agents > D000894 - Anti-Inflammatory Agents, Non-Steroidal > D016861 - Cyclooxygenase Inhibitors C78272 - Agent Affecting Nervous System > C241 - Analgesic Agent > C2198 - Nonnarcotic Analgesic D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents D002491 - Central Nervous System Agents > D000700 - Analgesics D000893 - Anti-Inflammatory Agents D004791 - Enzyme Inhibitors
Sudoxicam
4-(2,5-Dihydroxypyrrol-1-yl)-N-(1,3-thiazol-2-yl)benzenesulfonamide
2-Bromo-6,8-dihydroxy-7-propyl-9H-pyrrolo[2,1-b][1,3]benzoxazine-9-one
4-[(2-methoxycarbonyl-5-thiophen-2-ylthiophen-3-yl)amino]-4-oxobut-2-enoic acid
4-(2,3-dichlorophenyl)-5,7-dihydro-2-methyl-5-oxo-Furo[3,4-b]pyridine-3-carboxylic acid
HTS 01037
HTS01037 is an inhibitor of fatty acid binding; and a competitive antagonist of protein-protein interactions mediated by AFABP/aP2 with a Ki of 0.67 μM.
1,1-DIOXOBENZO[B]THIOPHEN-2-YLMETHYL N-SUCCIMIDYL CARBONATE
2,4-Dichloro-5-(1-piperidinylsulfonyl)benzoic acid
N-(4-acetylphenyl)-2-(2,4-dichlorophenoxy)acetamide
tetrasodium,2-(1,2-dicarboxylatoethylamino)butanedioate
4-{[3-(Trifluoromethyl)pyridin-2-yl]oxy}benzenesulfonyl chloride
5-(2-CHLORO-6-METHYLPYRIMIDIN-4-YL)-4-(4-CHLOROPHENYL)-4H-1,2,4-TRIAZOLE-3-THIOL
ethyl 3-bromo-7-(trifluoromethyl)imidazo[1,2-a]pyrimidine-6-carboxylate
ETHYL 5-BROMO-3-(2-CARBOXY-VINYL)-1H-INDOLE-2-CARBOXYLATE
5-Bromo-3-methoxy-2-(pyridin-4-ylmethoxy)benzoic acid
3-[[1-(3,4-dichlorophenyl)ethylideneamino]oxymethyl]benzoic acid
BIS(TRICYCLOHEXYLPHOSPHINE)-3-PHENYL-1H-INDEN-1-YLIDENERUTHENIUM(II)DICHLORIDE
5-Bromo-N-(4-methoxybenzyl)-3-nitropyridin-2-amine
6-chloro-N-cyclopentyl-5-iodo-2-methylpyrimidin-4-amine
ethyl 2-(broMoMethyl)-8-cyano-7-MethoxyiMidazo[1,2-a]pyridine-3-carboxylate
2-AMino-3-hydroxy-2-(hydroxyMethyl)propyl Phosphate BariuM Salt
1-(4-(5-Bromopyridin-2-yl)piperazin-1-yl)-2,2,2-trifluoroethanone
(5r)-3-(3-fluoro-4-iodophenyl)-5-hydroxymethyloxazolidin-2-one
4-[(4-CHLORO-2,5-DIMETHYLPHENYL)THIO]-3-NITROBENZOIC ACID
Sudoxicam
C78272 - Agent Affecting Nervous System > C241 - Analgesic Agent > C2198 - Nonnarcotic Analgesic
5-[(6-Nitro-1,3-benzodioxol-5-yl)hydrazinylidene]-2-sulfanylidene-1,3-diazinane-4,6-dione
(E)-4-[(2-methoxycarbonyl-5-thiophen-2-ylthiophen-3-yl)amino]-4-oxobut-2-enoic acid
HTS01037 is an inhibitor of fatty acid binding; and a competitive antagonist of protein-protein interactions mediated by AFABP/aP2 with a Ki of 0.67 μM.
